Q2 EPS Estimates for AstraZeneca Raised by Zacks Research

AstraZeneca PLC (NASDAQ:AZN - Free Report) - Investment analysts at Zacks Research lifted their Q2 2026 earnings estimates for shares of AstraZeneca in a research report issued on Tuesday, May 20th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.21 for the quarter, up from their previous forecast of $1.19. The consensus estimate for AstraZeneca's current full-year earnings is $4.51 per share. Zacks Research also issued estimates for AstraZeneca's Q3 2026 earnings at $1.28 EPS and FY2026 earnings at $4.95 EPS.

Several other equities analysts have also recently commented on AZN. UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. Finally, Morgan Stanley began coverage on AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating on the stock. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $88.00.

AstraZeneca Stock Performance

Shares of AZN traded down $0.65 during mid-day trading on Friday, hitting $70.31. The company's stock had a trading volume of 2,350,779 shares, compared to its average volume of 5,170,223. The stock's 50-day moving average is $69.54 and its two-hundred day moving average is $69.57. The firm has a market capitalization of $218.06 billion, a PE ratio of 31.14, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. AstraZeneca has a one year low of $61.24 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The firm had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company's revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.06 EPS.

Institutional Trading of AstraZeneca

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Lindbrook Capital LLC raised its holdings in shares of AstraZeneca by 1.9% in the 1st quarter. Lindbrook Capital LLC now owns 7,574 shares of the company's stock worth $557,000 after buying an additional 141 shares in the last quarter. Cibc World Markets Corp lifted its holdings in shares of AstraZeneca by 1.1% during the fourth quarter. Cibc World Markets Corp now owns 12,901 shares of the company's stock valued at $845,000 after acquiring an additional 142 shares during the period. Principal Securities Inc. boosted its stake in shares of AstraZeneca by 0.5% in the 1st quarter. Principal Securities Inc. now owns 28,053 shares of the company's stock valued at $2,062,000 after purchasing an additional 142 shares in the last quarter. Sage Mountain Advisors LLC grew its holdings in shares of AstraZeneca by 3.4% in the 1st quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company's stock worth $329,000 after purchasing an additional 147 shares during the last quarter. Finally, Diversify Wealth Management LLC increased its position in shares of AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company's stock worth $295,000 after purchasing an additional 153 shares in the last quarter. Institutional investors own 20.35% of the company's stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.